Viridian Therapeutics EBITDA 2011-2026 | VRDN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Viridian Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-363 M	-298 M	-254 M	-134 M	-79.6 M	-40.3 M	-41.7 M	-32.8 M	-26.2 M	-9.48 M	-11 M	-6.82 M	-298 K	-2.95 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-298 K	-363 M	-92.9 M

Quarterly EBITDA Viridian Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-93.7 M	-	-	-	-55.8 M	-	-	-	-72.4 M	-	-29.6 M	-29.5 M	-25.8 M	-	-14 M	-17.9 M	-18.5 M	-	-5.35 M	-6.31 M	-7.93 M	-	-11.1 M	-8.84 M	-11.7 M	-	-9.05 M	-8.76 M	-4.55 M	-	-5.79 M	-7.25 M	-6.87 M	-	-3.98 M	-3.35 M	-3.46 M	-	-2.99 M	-2.4 M	-2.57 M	-	-1.6 M	-2.78 M	-131 K	-	-275 K	-22.4 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-22.4 K	-93.7 M	-14.8 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Assembly Biosciences ASMB	-12 M	$ 28.46	3.45 %	$ 319 M	USA
Ascendis Pharma A/S ASND	-452 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	-166 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Galera Therapeutics GRTX	-20.1 M	-	-32.59 %	$ 7.61 M	USA
Pharming Group N.V. PHAR	74 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
Autolus Therapeutics plc AUTL	-234 M	$ 1.37	-4.2 %	$ 350 M	Britain
Kamada Ltd. KMDA	-696 K	$ 8.5	-1.39 %	$ 260 M	Israel
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Benitec Biopharma BNTC	-9.77 M	$ 10.98	-4.52 %	$ 452 M	USA
Inventiva S.A. IVA	-52.1 M	$ 5.78	-4.3 %	$ 138 M	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Compugen Ltd. CGEN	-34.6 M	$ 2.09	-0.95 %	$ 195 M	Israel
Tiziana Life Sciences PLC TLSA	-27.4 M	$ 1.21	-3.97 %	$ 71.5 M	Britain
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
PainReform Ltd. PRFX	-7.2 M	$ 2.28	-0.44 %	$ 1.03 M	Israel
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Foghorn Therapeutics FHTX	-83.1 M	$ 5.0	2.25 %	$ 315 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
AbCellera Biologics ABCL	-199 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
BioMarin Pharmaceutical BMRN	489 M	$ 54.13	-1.64 %	$ 10.4 B	USA
Curis CRIS	-44.3 M	$ 0.77	1.89 %	$ 4.86 M	USA
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	-180 M	$ 1.52	-5.59 %	$ 178 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	242 M	$ 7.7	-5.87 %	$ 1.29 B	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Cellectis S.A. CLLS	-131 M	$ 3.34	-4.02 %	$ 116 M	France
Arbutus Biopharma Corporation ABUS	-76.7 M	$ 4.24	-2.97 %	$ 704 M	Canada
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Cardiff Oncology CRDF	-48.6 M	$ 1.8	-1.1 %	$ 120 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Cabaletta Bio CABA	-73.2 M	$ 2.94	-3.29 %	$ 3.43 M	USA
Iterum Therapeutics ITRM	-18.7 M	$ 0.16	-5.45 %	$ 3.15 M	Irlanda
Brickell Biotech BBI	-6.32 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA